useful information for all medical professionals on contact dermatitis due to cosmetics and external medicines.

Source: Arerugi - Category: Allergy & Immunology Authors: Tags: Arerugi Source Type: research

Related Links:

In conclusion, novel woad extracts were developed and shown to have anti-inflammatory properties in a contact hypersensitivity animal model and human keratinocytes. The production of such extracts and further characterization of their specific properties will enable determination of their potential dermatological effects in the treatment of inflamed and irritated skin. PMID: 32250439 [PubMed - as supplied by publisher]
Source: Acta Derm Venereol A... - Category: Dermatology Authors: Tags: Acta Derm Venereol Source Type: research
BACKGROUND: Atopic dermatitis (AD) is known to negatively influence the mental health of patients. However, only a few studies have explored the influencing factors for psychiatric problems among adolescents with AD. OBJECTIVE: W e aimed to assess ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
We report the case of a 20-year-old man with atopic dermatitis treated with dupilumab for half a year, who presented with sudden onset of dizziness, nausea, and slight cerebellar ataxia. Brain magnetic resonance imaging revealed acute infarction in the bicerebellar hemispheres.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research
Ingredients in toothpaste may cause allergic and irritant contact stomatitis (Table I). Flavourings are most commonly incriminated, as they are present in 95% of toothpastes.1 Less frequently, cinnamon, fluoride and Anethole (Anise camphor) have been suggested to cause local irritation.2,3 Pruritis and flexural dermatitis to toothpaste has been reported in a 50-year-old woman sensitized to stannous fluoride (SnF2) on patch testing.4
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
Conditions:   Chronic Inflammatory Disease;   Angioedema;   Severe Asthma;   Lupus;   Atopic Dermatitis;   Psoriatic Arthritis;   Multiple Sclerosis;   Systemic Sclerosis Interventions:   Genetic: Biobanking with genetic analysis;   Other: SF-12 questionnaire Sponsors:   University Hospital, Lille;   FHU IMMINeNT Not yet recruiting
Source: - Category: Research Source Type: clinical trials
The restrictions on movement and normal interaction owing to COVID-19 pose a distinct challenge to the traditional clinical trial model, as patients, investigators and clinical staff are either confined to their homes or seeking to avoid healthcare settings.    Those running clinical trials over the past weeks have had to adapt rapidly by fast-tracking digital capabilities to ensure continued delivery. With the future of existing trials hanging in the balance, some have been pivoting to remote delivery – sometimes in the space of under a week.   Speaking at eyeforpharma Virtual, a digital versio...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
Healthcare companies Sanofi and Regeneron announced on Friday more encouraging results for their Dupixent product used to treat severe atopic dermatitis, often commonly known as eczema.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Authors: PMID: 32242919 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Tags: Br J Dermatol Source Type: research
Authors: Asfour L, Yiu ZZN, Warren RB Abstract Introduction: Skin conditions are common and highly varied in their etiology; therefore, a diverse array of therapeutics are utilized. Drug safety studies in dermatology can be challenging as there are over 3000 diagnoses to consider. As a result, dermatologists rely on data from multiple sources including clinical trials and real-world evidence.Areas covered: In this review, we cover the main sources of safety data available, their strengths and weaknesses and how dermatologists should utilize such data. We use real-world examples of the different types of adverse eve...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Pharos Excimer Laser, Model: EX-308 - Product Usage: The Pharos EX-308 Excimer Laser System is designed to treat the skin disorders psoriasis, vitiligo, atopic dermatitis, and leukoderma using phototherapy. The excimer laser system produces collimated 308 nm radiation, within the invisible region of the electromagnetic spectrum. The UV radiation falls within the range of ultraviolet B (UVB), which is used to treat photo-responsive skin disorders.
Source: Medical Device Recalls - Category: Medical Devices Source Type: alerts
More News: Allergy & Immunology | Dermatitis | Dermatology | Japan Health | Science